|Bid||2.95 x 1000|
|Ask||3.45 x 800|
|Day's Range||3.00 - 3.21|
|52 Week Range||2.70 - 4.99|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The New York-based company said it had a loss of 88 cents per share. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Heat Biologics Inc (NASDAQ: HTBX ) stock was trading ...
In 2017, Tonix (TNXP) announced the first patient was enrolled in the Phase 3 HONOR study of TNX-102 SL 5.6 mg for the treatment of posttraumatic stress disorder (PTSD, NCT03062540). The HONOR trial is a 12-week, multicenter, randomized, double blind, placebo controlled, fixed dose study of 5.6 mg TNX-102 SL (2 x 2.8 mg tablets) taken at bedtime. Approximately 550 subjects who have served in the military and meet a diagnosis of PTSD according to the Clinician-Administered PTSD Scale (CAPS-5) for DSM-5 are eligible to enroll.
The New York-based company said it had a loss of 71 cents per share. Losses, adjusted for non-recurring costs, were 67 cents per share. For the year, the company reported that its loss narrowed to $21.1 ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP ...
Tonix Pharmaceutical Holdings Corp. (TNXP) recently announced the company had completed a pre-IND meeting with the U.S. Food and Drug Administration (FDA) regarding the use of TNX-102 SL (cyclobenzaprine HCl sublingual tablet) for agitation in Alzheimer’s disease (AD). Agitated behaviors (e.g., irritability, restlessness, aggression) are a significant issue in patients with AD.
The most recent earnings announcement Tonix Pharmaceuticals Holding Corp’s (NASDAQ:TNXP) released in September 2017 revealed company earnings became less negative compared to the previous year’s level as a result ofRead More...
Tonix Pharmaceutical Holdings Corp. (TNXP) announced earlier this year that the company had successfully synthesized a smallpox-preventing vaccine. While always thought to be based on a cowpox virus, new research has shown that the horsepox virus may be the ancestor of the smallpox vaccine, thus lending further support to Tonix’s use of a horsepox virus for a new smallpox vaccine. Edward Jenner was a British physician who is known as the father of modern vaccination.
On a per-share basis, the New York-based company said it had a loss of 77 cents. Losses, adjusted for non-recurring costs, were 70 cents per share. The company's shares closed at $3.66. A year ago, they ...
Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) announced a loss of -$24.90M in its most recent earnings update. Although some investors expected this, their belief in the path to profitability for TNXPRead More...
Tonix (TNXP) is a pharmaceutical company focused on the development of products to address major public health challenges. The company’s lead product, Tonmya® (TNX-102 SL), is currently being developed as a treatment for posttraumatic stress disorder (PTSD). A Phase 3 clinical trial in military-related PTSD (the HONOR study) was initiated in the first quarter of 2018, and we anticipate an unblinded interim analysis taking place in the first half of 2018.
On a per-share basis, the New York-based company said it had a loss of 65 cents. The company's shares closed at $3.15. A year ago, they were trading at $25.60. _____ This story was generated by Automated ...